





Introduction to oncology clinical development from a quantitative modelling perspective

The health care sector is quickly becoming a major employment opportunity for quantitative scientist, due to the increasing digitalisation of patient-level data and to the pressing need for health care to be provided more efficiently and effectively. In this context, quantitative modelling is a cornerstone for health care innovation at all levels. In this talk we will illustrate the main contributions of quantitative modelling to discovery of new molecular entities and to the clinical development process needed to experimentally measure their main benefits and potential harms in patient populations. We will then dive deeper in some basic statistical considerations for the design of clinical trials, with emphasis on the opportunities afforded by the availability of historical and realworld evidence data. All concepts and examples will be illustrated in plain language, with a view to conveying simple and direct messages to the broadest audience.

Fabio Rigat, PhD

Oncology Biometrics GI Strategy Head, Executive Director, AstraZeneca 7 dicembre 2022, ore 12:00 (precise)
Aula MS1 (DICAr)